Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Key claim: Tagraxofusp is being studied as multi-cycle post-allogeneic transplant maintenance to prevent relapse in patients with CD123-positive myelofibrosis, CMML, AML, and MDS.
Abstract
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.
Why this matters
Post-allo-HCT relapse is the dominant failure mode for transplanted MF/CMML patients, and the maintenance toolkit remains thin — mostly HMA, pegINFa, and JAK inhibitors. Extending an approved CD123-directed agent into post-transplant maintenance opens a targeted, non-HMA option specifically for CD123+ MF and CMML, broadening the relapse-prevention menu without changing the upstream decision to transplant.